SLRN - Earnings announcements

Topline data from Phase 3 ONWARD trials for Alumis' ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026 Evaluation underway of development plan for ACELYRIN's lonigutamab to confirm differentiation in a capital efficient manner Pro forma cash position of approximately $737 million as of December 31, 2024, provides runway into 2027, beyond expected multiple clinical readouts for highly differentiated late-stage portfolio Alumis and ACELYRIN stockholders to own ~55% and ~45%, respectively, of combined company on a fully diluted basis Combined company wi

Totality of data observed with subcutaneous lonigutamab in Thyroid Eye Disease (TED) patients demonstrate potential for efficacy in line with standard of care and a more favorable safety profile Conducted positive end of Phase 2 FDA meeting; Phase 3 program expected to be initiated in Q1 2025 Topline Phase 3 data expected in second half of 2026; cash runway expected through mid-2027 Conference call to review unmet need in TED, new Phase 2 data and Phase 3 program design to be held today, January 6, 2025, at 4:30 PM ET LOS ANGELES, Jan. 06, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery

Topline data from Phase 2b/3 trial of izokibep as a treatment for non-infectious non-anterior uveitis expected in December 2024 Positive lonigutamab EOP2 FDA interaction completed and initiation of subcutaneous Phase 3 development program in thyroid eye disease (TED) expected in Q1 2025 Cash, cash equivalents, and short-term marketable securities at September 30, 2024 of $562.4 million projected to provide cash runway to mid-2027 Company to hold webcast and conference call at 4:30pm ET today LOS ANGELES, Nov. 13, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the dev

LOS ANGELES, Nov. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a conference call on Wednesday, November 13, 2024 at 4:30 p.m. ET to discuss its third quarter 2024 financial results and other corporate updates. A live webcast of the conference call will be available on the Company's website under Events & Presentations. A replay of the webcast will be available on the Company's website for 90 days. About ACELYRINACELYRIN, INC. (NASDAQ:SLRN) is focused on providing patients life-changing new treatment options by i

Phase 3 trial of izokibep in hidradenitis suppurativa met primary endpoint of HiSCR75 at 12 weeks Company to prioritize development of lonigutamab; dose confirmation ongoing in Phase 2 trial with plans to initiate Phase 3 program in Q1 2025 Cash, cash equivalents, and short-term marketable securities at June 30, 2024 of $635.2 million; projected to extend cash runway to mid-2027 Company to hold webcast and conference call at 5:00pm ET today LOS ANGELES, Aug. 13, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that the Phase 3 tria

LOS ANGELES, Aug. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a conference call on Tuesday, August 13, 2024 at 5:00 p.m. ET to discuss its second quarter 2024 financial results and provide a corporate update. A live webcast of the conference call will be available on the Company's website under Events & Presentations. A replay of the webcast will be available on the Company's website for 90 days. About ACELYRIN, INC.ACELYRIN, INC. (NASDAQ:SLRN) is a Los Angeles area-based late-stage clinical biopharma company –

LOS ANGELES, April 29, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a conference call on Monday, May 13, 2024 at 4:30 p.m. ET to discuss its first quarter 2024 financial results and provide a corporate update. A live webcast of the conference call will be available on the Company's website under Events & Presentations. A replay of the webcast will be available on the Company's website for 90 days. About ACELYRIN, INC.ACELYRIN, INC. (NASDAQ:SLRN) is a Los Angeles area-based late-stage clinical biopharma company – wit

Rapid improvements demonstrated for proptosis, clinical activity scores, and diplopia versus placebo with a favorable safety profile Phase 2b/3 trial to be initiated in the second half of 2024 Conference call to review these data to be held at 8:30 a.m. ET today LOS ANGELES, March 20, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced positive proof-of-concept data from an ongoing Phase 1/2 trial of lonigutamab in thyroid eye disease (TED). Lonigutamab is a subcutaneously (SC) delivered humanized IgG1 monoclonal antibody targeting t

Portfolio of programs continues to advance with data from both the global Phase 2b/3 trial for izokibep in PsA and proof-of-concept for lonigutamab as a subcutaneous treatment for thyroid eye disease expected in first quarter 2024 Additional PsA Phase 2 long-term data on clinical measures of disease resolution and quality of life to be presented at 2023 Annual Meeting of the American College of Rheumatology Cash, cash equivalents and short-term marketable securities totaled $788.4 million on September 30, 2023, providing runway through multiple key milestones across all three clinical programs     Company to host conference call and webcast at 4:30 p.m. ET today LOS ANGELES, Nov.

LOS ANGELES, Oct. 31, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a conference call on Tuesday, November 7, 2023 at 4:30 p.m. ET to discuss its third quarter 2023 financial results and provide a corporate update. A live webcast of the conference call will be available on the Company's website under "Events" at the following link: https://www.acelyrin.com/events. A replay of the webcast will be available on the Company's website for 90 days. About ACELYRINACELYRIN, INC. (NASDAQ:SLRN) is a Los Angeles area-based late

The primary endpoint of HiSCR75 at week 16 did not meet statistical significance in the Non-Responder Imputation (NRI) primary analysis. HiSCR75 did meet statistical significance at week 16 in a Last Observation Carried Forward sensitivity analysis. HiSCR response rates of izokibep 160mg weekly (QW) were consistent with Part A open label results, demonstrating early onset of HiSCR100 at week 4, increasing through week 12 to 38% of patients in the Independently Conducted Pre-Planned Interim Analysis. Response was dose ordered, and safety was consistent with prior izokibep experience and not dose-limiting. Izokibep appears to be demonstrating consistent early and high orders of response

LOS ANGELES, Aug. 07, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a conference call on Monday, August 14, 2023 at 4:30 p.m. ET to discuss its second quarter 2023 financial results and provide a corporate update. A live webcast of the conference call will be available on the Company's website under "Events" or at https://www.acelyrin.com/events. A replay of the webcast will be available on the Company's website for 90 days. About ACELYRINACELYRIN, INC. is a Los Angeles area-based late-stage clinical biopharma compan